Morgan Comments on Tax Implications of Benefit Changes Due to Teleworking
23 October 2020
Partner Belinda Morgan was quoted in a SHRM article, “Avoiding Tax Problems with New Benefits,” about how employers can inadvertently create tax liabilities by offering new benefits to teleworking employees.
Considering how quickly employers needed to respond to the issuance of work-from-home orders at the start of pandemic, Morgan said, it’s “not surprising” that the tax treatment of a particular benefit wasn’t at the top of anyone’s mind at the time. But now that work-from-home arrangements and other workforce changes have become routine, employers may want to consider whether these new benefits are a normal business expense or a “fringe” benefit that could create tax liabilities for both the employer and the employee.
“Small rewards for good performance, such as an employer-branded hat or a similar inexpensive item, will be nontaxable,” she said. “If that reward is payable in the form of a $5 Starbucks gift card, however, it will be taxable,” even if the monetary value of those two gifts is the same.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”